Eiko LifeSciences Reports Strong Q1 Results, Announces Board Changes and Capital Increase
Eiko LifeSciences Limited reported its Q1 FY2025-26 results. Consolidated revenue was ₹1,071.15 lakhs, slightly down from ₹1,075.04 lakhs in Q1 last year. However, profit after tax significantly increased to ₹111.74 lakhs from ₹37.13 lakhs. EPS rose to ₹0.66 from ₹0.29. The company announced board changes including the resignation of Mr. Umesh More and appointment of Mr. Sumukh Prabhakar Vartak as Whole Time Director. The board approved an increase in authorized share capital from ₹14 crore to ₹20 crore, subject to shareholder approval. The company operates in specialty chemicals and logistics segments, with the former contributing ₹840.22 lakhs in revenue and the latter ₹230.93 lakhs.
29Jul 25
Eiko LifeSciences Announces Board Changes and Expansion Plans at 48th AGM
Eiko LifeSciences Limited has announced significant board changes including the resignation of Mr. Umesh More and appointment of Mr. Sumukh Prabhakar Vartak as Whole Time Director. The company plans to increase its Authorized Share Capital from Rs. 14 crore to Rs. 20 crore. For Q1 FY 2025-26, the company reported a consolidated net profit of Rs. 111.74 lakhs, up from Rs. 37.13 lakhs in the same quarter last year. The 48th AGM is scheduled for September 5, 2025, where these changes and financial results will be addressed.